investigators, CATALYST & Dark, P 2022, ' Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. ', The Lancet. Respiratory medicine, vol. 10, no. 3, pp. 255-266 . https://doi.org/10.1016/S2213-2600(21)00460-4 The Lancet. Respiratory Medicine